Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow ...

Verona Pharma plc's Ohtuvayre, approved for COPD, has driven the Pharma's stock up >350%, but intense competition and high valuation prompted a downgrade to “Hold”. Despite early success ...

LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq ... “We are pleased that Oaktree and ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

If you need financial support to pay for Ohtuvayre or help understanding your insurance coverage, assistance is available. For example: A program called Verona Pathway Plus is available for Ohtuvayre.

Ohtuvayre (ensifentrine ... talk with your doctor or pharmacist. A program called Verona Pathway Plus may also be available. »Learn more about saving on your prescriptions.

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) ...

(RTTNews) - Verona Pharma plc (VRNA), Friday announced some strategic changes in its capital structure, increasing the company's financial flexibility and simplifying its balance sheet. The ...

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.

Verona Pharma is a biopharmaceutical company ... of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product ...

Morningstar brands and products Company Portfolio ...